linjc16/ctgov huggingface dataset:
Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to generate evidence regarding hypophosphatemia after iron infusion in lung transplant recipients in context of anemia and/or iron deficiency.

Official Title
-----------------
Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia

Conditions
-----------------
Hypophosphatemia

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lung transplant recipient treated at the University Hospital Zurich between 2015 until 2022 Exclusion Criteria: Denied general consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of serum phosphate level | Change of serum phosphate level before and after iron infusion | Baseline and up to 90 days after iron infusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of urin phosphate level | Change of urin phosphate level before and after iron infusion | Baseline and up to 90 days after iron infusion | 
| Change of hemoglobin | Change of hemoglobin level before and after iron infusion | Baseline and up to 90 days after iron infusion | 
| Change of mean corpuscular volume (MCV) | Changes of serum MCV level before and after iron infusion | Baseline and up to 90 days after iron infusion | 
| Change of mean corpuscular hemoglobin (MCH) | Change of serum MCH level before and after iron infusion | Baseline and up to 90 days after iron infusion | 
| Change of serum magnesium | Change of serum magnesium level before and after iron infusion | Baseline and up to 90 days after iron infusion | 
| Change of serum and urin calcium | Change of serum and urin calcium level before and after iron infusion | Baseline and up to 90 days after iron infusion | 
| Change of serum albumin | Change of serum albumin level before and after iron infusion | Baseline and up to 90 days after iron infusion | 
| Complications after iron infusion | Number of patients with complications due to hypophosphatemia after iron infusion (Hospitalization, hypoxia, fracture due to hypophosphatemia) | 2015-2022 | 
| Predictors | Analysis of possible predictors for the decrease of serum phosphate levels after iron infusion | baseline and up to 90 days after iron infusion | 
| Therapeutic management | Descriptive analysis of therapeutic management of hypophosphatemia after iron infusion | 2015 to 2022 |
Pain Management in Elderly Patients With or Without Cognitive Frailty Hospitalized ALGOGER

Study Overview
=================
Brief Summary
-----------------
Today, the standard treatment is to operate on patients suffering from a fracture of the upper end of the femur. The aim of treatment is to enable immediate mobilization and weight-bearing, and as rapid a return as possible to normal living conditions. Surgery is the best treatment option. It maximizes the chances of functional recovery and, by stabilizing the fracture, reduces pain: it is the most effective and longest-lasting analgesic. Adequate analgesia in elderly patients with femoral neck fractures has a beneficial effect. In particular, a lower probability of death has been shown in cervical fracture patients receiving opioids than those not receiving them. Pain management is a matter of protocol in the UPOG department of the CHU de Nîmes. Pain prevention appears to improve morbidity and mortality. Cognitive fragility, such as neurocognitive disorders, confusion or long-term use of psychotropic drugs, appear to be confounding factors in pain management. The investigators therefore wished to observe whether the presence of cognitive fragility has an impact on pain management on the ward, despite protocol-based management.

Official Title
-----------------
Retrospective Study of Protocol-based Pain Management in Elderly Patients With or Without Cognitive Frailty Hospitalized at UPOG for Fracture of the Upper Extremity of the Femur in 2022

Conditions
-----------------
Cognitive Deterioration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged > 75 years Hospitalized for a fracture of the upper extremity of the femur at the UPOG of the CHU de Nîmes during 2022 Exclusion Criteria: Opioid allergy No surgical management of fracture Long-term treatment with high-dose opiates Patient has objected to the use of his or her data.

Ages Eligible for Study
-----------------
Minimum Age: 76 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morphine sulfate equivalent rate in each group, mg/day | mg/day | Pre-operative | 
| Morphine sulfate equivalent rate in each group, mg/day | mg/day | Early post-operative between Day 0 and Day 3 | 
| Morphine sulfate equivalent rate in each group, mg/day | mg/day | Late post-operative between Day 4 and day 7 |
Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions

Study Overview
=================
Brief Summary
-----------------
Endometrial carcinoma (EC) is the 6th most commonly occurring cancer in women and the 15th most common cancer overall According to facts derived from Globocan for the year 2020.The overall incidence was 417,367 and 97,370 died due to it. There were more than 417,000 new cases of endometrial cancer in 2020 .EC incidence is predicted to continue to rise in the coming decades, in particular among low and middle-income countries. SOX17 protein (SRY-box 17) is a member of the SRY-related HMG-box (SOX) family of transcription factors that controls the first step of gene expression and regulates cellular growth and differentiation in the endoderm, during hematopoiesis, and in the cardiovascular system E-Cadherin is a calcium-dependent cell adhesion protein (predicted molecular weight of 97 kDa) that plays a vital role in cell migration and proliferation. The E-cadherin epithelial cell adhesion protein is a tumor suppressor that has an important role in tumor metastasis The loss of expression of E-Cadherin during the epithelial mesenchymal transition (EMT) is often thought to promote metastasis by allowing the dissociation and invasion of cancer cells The aim of this study is: To evaluate accuracy of SOX17 expression in neoplastic and hyperplastic endometrial lesions. To correlate SOX17 expression with some clinical and pathological parameters of endometrial carcinoma. To evaluate E-Cadhrin expression and its relation to SOX17 in neoplastic and hyperplastic lesions

Official Title
-----------------
Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions

Conditions
-----------------
Variable Endometrial Lesions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Specimens of total abdominal hysterectomy and bilateral salpingio-oopherectomy of endometrial carcinoma patients 2. D&C of endometrial tissue suspected of hyperplastic or neoplastic lesions Exclusion Criteria: • Specimens with insufficient clinical data. Specimens with extensive necrosis

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions | Immunohistochemical expression of SOX17 and E-Cadherin in Variable Endometrial Lesions | one or two days after staining sections with markers |
Supracondylar Femur Fracture After DDH

Study Overview
=================
Brief Summary
-----------------
incidence of ipsilateral Supracondylar femoral fractures after cast removal for Developmental dysplasia of the hip (DDH) surgery

Official Title
-----------------
Ipsilateral Supracondylar Femoral Insufficiency Fractures After Cast Removal of Developmental Dysplasia of the Hip Surgery

Conditions
-----------------
DDH

Intervention / Treatment
-----------------
* Procedure: DDH surgery and casting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 1-7 years old Primary DDH Exclusion Criteria: • Paralytic hip DX in cases of (Cerebral palsy,Meningomyelocele,Neuropathy or Myopathy) Recurrent cases of DDH Past history of ipsilateral distal femoral fractures

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: incidence of ipsilateral Supracondylar femoral fractures after cast removal for Developmental dysplasia of the hip (DDH) surgery
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DDH surgery<br>DDH surgery open reduction and casting | Procedure: DDH surgery and casting<br>* DDH surgery and casting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with supracondylar femoral fracture | Number of patients with supracondylar femoral fracture | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DDH, insufficiency fractures
Examination of Trends in Multiple Myeloma Trial Patient Experiences

Study Overview
=================
Brief Summary
-----------------
Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. This study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. Data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future multiple myeloma patients.

Official Title
-----------------
Analyzing Factors of Patient Involvement in Multiple Myeloma Clinical Trials

Conditions
-----------------
Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed Patient has been diagnosed with multiple myeloma Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form Pregnant, breastfeeding or expecting to conceive within the projected duration of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with multiple myeloma who decide to enroll in clinical trial |  | 3 Months | 
| Rate of patients with multiple myeloma who remain in clinical trial to completion |  | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple myeloma
European Aortic Data Collection Project

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and performance of Cook's various Custom-Made Stent-graft Devices (CMD) used for endovascular treatment of the aorta and related diseases by collecting information on the real-world use of the devices. The study results will be used to support the continuation of the CMDs on the market. In addition, the study will support the manufacturers obligation for post market product surveillance as well as Cook's technology development.

Official Title
-----------------
European Aortic Data Collection Project

Conditions
-----------------
Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Chronic Aortic Dissection

Intervention / Treatment
-----------------
* Procedure: Endovascular Aortic Treatments


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients who will be treated with a Cook CMD Exclusion Criteria: Patients who declare they are unable to complete clinical follow-up visit at the time of enrollment, or Patients or his/her legally authorized representative objects to extraction of patient's data from the medical record, or unwilling to sign the Informed Consent.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endovascular Aortic Treatments|Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of treatment success | Procedural treatment success is defined as successful access to the arterial system using remote arterial exposure, percutaneous technique or open surgical conduits. Success is also defined as successful delivery and deployment of the aortic graft and all stent components, side branch catheterization and placement of bridging stents and patency of all aortic modular stent graft components and intended side branch components. | 12 months | 
| Rate of safety outcomes | Safety outcomes is defined as freedom from major adverse events (all-cause mortality, myocardial infarction, disabling stroke, renal failure requiring new-onset dialysis, respiratory failure requiring prolonged (>24hrs) mechanical ventilation or reintubation, paraplegia, bowel ischemia requiring surgical resection or not resolving with medical therapy) | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Complex aortic repair, Aortic aneurysm, Aortic dissection, Fenestrated/branched endograft, Custom-made endovascular graft
Obsidio™ Conformable Embolic Registry

Study Overview
=================
Brief Summary
-----------------
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.

Official Title
-----------------
A Prospective, Post-Approval, Open-Label, Multi-Center United States (US) Registry to Evaluate the Effectiveness and Safety of Obsidio in Clinical Practice

Conditions
-----------------
Hypervascular Tumors, Bleeding, Hemorrhage

Intervention / Treatment
-----------------
* Device: Obsidio™ Conformable Embolic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old Patient has the ability to comprehend and willingness to sign the informed consent form. Patients being treated for control of bleeding /hemorrhage unable to consent prior to their procedure, can be enrolled if the informed consent is provided and signed within 72 hrs. of the index procedure Patient is to undergo or has undergone embolization with Obsidio™ Conformable Embolic Patient is willing and able to comply with protocol requirements, including all procedures, clinical evaluations, and follow up visit Exclusion Criteria: Patient refuses participation Patient has a life expectancy < 30 days Contraindications to receiving Obsidio Conformable Embolic per the Instructions For Use (IFU) Embolization for uterine fibroids, prostate artery, genicular artery, ovarian vein, spermatic vein, pulmonary arteriovenous malformations, bronchial artery, varicocele, asymptomatic benign tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All subjects<br> | Device: Obsidio™ Conformable Embolic<br>* Embolization with Obsidio™ Conformable Embolic.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary effectiveness endpoint | The primary effectiveness endpoint is technical success which is defined as occlusion of the target vessel after embolization with Obsidio™ Conformable Embolic assessed via angiography immediately following the index procedure | Immediately following index procedure | 
| Primary safety endpoint | The primary safety endpoint is freedom from major adverse events defined as non-target embolization events that meet serious adverse event criteria, unintended target organ or soft tissue infarction, vessel perforation/injury and catheter entrapment through 30 days of the index procedure. | 30 days following index procedure |
Working Memory Quality of Attentional Templates

Study Overview
=================
Brief Summary
-----------------
In this line of research, the researchers are examining a basic science question regarding the working memory representations underlying visual search using a positive template (looking for a target) or a negative template (avoiding a distractor).

Detailed Description
-----------------
When finding a search target, receiving a target cue or distractor cue can increase search efficiency. Critically, in order to use these cues to help search performance, they must be maintained in working memory. The researchers are examining whether the working memory representations are of similar quality for a target cue (positive template) or distractor cue (negative template).

Official Title
-----------------
Working Memory Quality of Attentional Templates

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Visual Search Cue Type


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: normal or corrected to normal visual acuity, normal color vision Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: All participants receive each level of visual cue type.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Within-subjects Cue Type<br>Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search. | Behavioral: Visual Search Cue Type<br>* Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Button Press Reaction Time | Speed to respond correctly to the target- after participant finds the target shape on a computer screen, they press a button to indicate what shape they see | Day 1 (single day of testing) | 
| Button Press Accuracy | Accuracy of responses to target item-measure whether the participants presses the correct button which corresponds to the target shape presented on the computer screen or the incorrect button | Day 1 (single day of testing) | 
| Working Memory Report Quality | Accuracy of computer clicks on a set of colors to indicate memory of cue presented | Day 1 (single day of testing) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
attention, visual search, working memory